These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32661074)

  • 1. Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines.
    Steel R; Buchak L; Eyal N
    J Med Ethics; 2020 Dec; 46(12):808-812. PubMed ID: 32661074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenge Trials: What Are the Ethical Problems?
    Hausman DM
    J Med Philos; 2021 Jan; 46(1):137-145. PubMed ID: 33236048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccines: ethical framework concerning human challenge studies.
    Calina D; Hartung T; Docea AO; Spandidos DA; Egorov AM; Shtilman MI; Carvalho F; Tsatsakis A
    Daru; 2020 Dec; 28(2):807-812. PubMed ID: 32851596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enrolling Minors in COVID-19 Vaccine Trials.
    Mintz K; Jardas E; Shah S; Grady C; Danis M; Wendler D
    Pediatrics; 2021 Mar; 147(3):. PubMed ID: 33334920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Payment in challenge studies: ethics, attitudes and a new payment for risk model.
    Grimwade O; Savulescu J; Giubilini A; Oakley J; Osowicki J; Pollard AJ; Nussberger AM
    J Med Ethics; 2020 Dec; 46(12):815-826. PubMed ID: 32978306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group.
    Jamrozik E; Littler K; Bull S; Emerson C; Kang G; Kapulu M; Rey E; Saenz C; Shah S; Smith PG; Upshur R; Weijer C; Selgelid MJ;
    Vaccine; 2021 Jan; 39(4):633-640. PubMed ID: 33341309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants.
    Rohrig A; Eyal N
    J Infect Dis; 2022 Mar; 225(6):934-937. PubMed ID: 34624095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure.
    Eyal N; Lipsitch M
    Clin Microbiol Infect; 2021 Mar; 27(3):372-377. PubMed ID: 33421580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dozens to be deliberately infected with coronavirus in UK 'human challenge' trials.
    Callaway E
    Nature; 2020 Oct; 586(7831):651-652. PubMed ID: 33082550
    [No Abstract]   [Full Text] [Related]  

  • 11. COVID-19 vaccine development: Time to consider SARS-CoV-2 challenge studies?
    Schaefer GO; Tam CC; Savulescu J; Voo TC
    Vaccine; 2020 Jul; 38(33):5085-5088. PubMed ID: 32540271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.
    Arashkia A; Jalilvand S; Mohajel N; Afchangi A; Azadmanesh K; Salehi-Vaziri M; Fazlalipour M; Pouriayevali MH; Jalali T; Mousavi Nasab SD; Roohvand F; Shoja Z;
    Rev Med Virol; 2021 May; 31(3):e2183. PubMed ID: 33594794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calling for an exponential escalation scheme in vaccine development for COVID-19.
    Wehling M
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1471-1472. PubMed ID: 32548679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Africa's need for more COVID-19 clinical trials.
    Makoni M
    Lancet; 2021 May; 397(10289):2037. PubMed ID: 34062137
    [No Abstract]   [Full Text] [Related]  

  • 16. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moving forward in clinical research with master protocols.
    Park JJH; Dron L; Mills EJ
    Contemp Clin Trials; 2021 Jul; 106():106438. PubMed ID: 34000408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncertainty, error and informed consent to challenge trials of COVID-19 vaccines: response to Steel
    Keren A; Lev O
    J Med Ethics; 2020 Dec; 46(12):813-814. PubMed ID: 32900846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.
    Eyal N
    Ethics Hum Res; 2020 Jul; 42(4):24-34. PubMed ID: 32441894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.